GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Daan Gene Co 002030.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

5.24

-0.57%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Daan Gene Co

Its shares trade on Shenzhen under the ticker 002030.SZ. It has been listed since 9 August 2004. In the fiscal year to 31 December 2025, it reported a net loss of CN¥744.4m. At that date it held total assets of CN¥8.51bn and shareholders' equity of CN¥7.14bn.

Daan Gene Co., Ltd. engages in the research, development, production and sales of clinical testing reagents and instruments; and provision of clinical laboratory services. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2004-08-09. The Company’s main products include fluorescence quantitative polymerase chain reaction (PCR) series, public health series, time-resolved series and enzyme-linked immunization series. The firm also provides independent medical clinical laboratory testing services. The firm operates its business in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
9 Aug 2004
Employees
3,580

Leadership

Pay as last reported

  • Mr. Xiwen JiangChief Scientific Officer, Deputy General Manager, Chief Research & Development Officer, Director, since 2021CN¥1.1m
  • Ms. Luo HuangGeneral Manager, Director, since 2021CN¥1.3m
  • Mr. Bin ZhangDeputy General Manager, Secretary of the Board, DirectorCN¥1.1m
  • Mr. Qian LongDirector
  • Mr. Jianbing FanIndependent DirectorCN¥120,000
  • Mr. Yunhai JiIndependent DirectorCN¥120,000
  • Mr. Zhengfu ZhuIndependent DirectorCN¥120,000
  • Mr. Zheqiang XueChairman of the Board
  • Ms. Dianhan WeiVice Chairman of the Board, since 2021
  • Mr. Weijie ZhangChief Financial Officer, Deputy General ManagerCN¥1.1m
  • Mr. Yang WangChief Marketing Officer, Deputy General ManagerCN¥1.1m

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
25
Environment
29
Social
32
Governance
14
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 3580 full-time employees
  • Headquartered in Guangzhou, Guangdong
  • Offers clinical testing reagents, instruments, and laboratory services

Weaknesses

  • Operates solely in the domestic market
  • No mention of international presence or expansion plans
  • No information on product innovation or R&D investment

Opportunities

  • Potential for growth in domestic health care sector
  • Expansion into international markets for clinical testing services
  • Increasing demand for biotechnology products in China

Threats

  • Dependence on domestic market may limit growth
  • Competition in biotechnology sector could increase
  • No information on regulatory challenges or market saturation

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.